Literature DB >> 29577414

Molecular insight into targeting the NK cell immune response to cancer.

Jai Rautela1,2, Fernando Souza-Fonseca-Guimaraes1,2, Soroor Hediyeh-Zadeh1,2, Rebecca B Delconte1,2, Melissa J Davis1,2, Nicholas D Huntington1,2.   

Abstract

Natural Killer (NK) cells have long been considered an important part of the anti-tumor immune response due to their potent cytolytic and cytokine-secreting abilities. To date, a clear demonstration of the role NK cells play in human cancer is lacking, and there are still very few examples of therapies that efficiently exploit or enhance the spontaneous ability of NK cells to destroy the autologous cancer cells. Given the paradigm shift toward cancer immunotherapy over the past decade, there is a renewed push to understand how NK cell homeostasis and function are regulated in order to therapeutically harness these cells to treat cancer. This review will highlight recent advancements in our understanding of how growth factors impact on NK cell development, differentiation, survival and function with an emphasis on how these pathways may influence NK cell activity in the tumor microenvironment and control of cancer metastasis.
© 2018 Australasian Society for Immunology Inc.

Entities:  

Keywords:  Cancer; IL-15; Interleukins; NK cells; STAT5; immune homeostasis

Mesh:

Year:  2018        PMID: 29577414     DOI: 10.1111/imcb.12045

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  7 in total

1.  Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer.

Authors:  Adele M Barr; Anabel Silva; Sandro Prato; Gabrielle T Belz; Eugene Maraskovsky; Adriana Baz Morelli
Journal:  Cancer Immunol Immunother       Date:  2020-05-09       Impact factor: 6.968

2.  Deficiencies in Natural Killer Cell Numbers, Expansion, and Function at the Pre-Neoplastic Stage of Pancreatic Cancer by KRAS Mutation in the Pancreas of Obese Mice.

Authors:  Kawaljit Kaur; Hui-Hua Chang; Paytsar Topchyan; Jessica Morgan Cook; Andre Barkhordarian; Guido Eibl; Anahid Jewett
Journal:  Front Immunol       Date:  2018-06-21       Impact factor: 7.561

Review 3.  Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

Authors:  Pascale André; Caroline Denis; Caroline Soulas; Clarisse Bourbon-Caillet; Julie Lopez; Thomas Arnoux; Mathieu Bléry; Cécile Bonnafous; Laurent Gauthier; Ariane Morel; Benjamin Rossi; Romain Remark; Violette Breso; Elodie Bonnet; Guillaume Habif; Sophie Guia; Ana Ines Lalanne; Caroline Hoffmann; Olivier Lantz; Jérôme Fayette; Agnès Boyer-Chammard; Robert Zerbib; Pierre Dodion; Hormas Ghadially; Maria Jure-Kunkel; Yannis Morel; Ronald Herbst; Emilie Narni-Mancinelli; Roger B Cohen; Eric Vivier
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

4.  Loss-of-Function in SMAD4 Might Not Be Critical for Human Natural Killer Cell Responsiveness to TGF-β.

Authors:  Lachlan P Healy; Gustavo R Rossi; Jai Rautela; Charlotte A Slade; Nicholas D Huntington; Ingrid M Winship; Fernando Souza-Fonseca-Guimaraes
Journal:  Front Immunol       Date:  2019-05-01       Impact factor: 7.561

Review 5.  Therapeutic Potential of Natural Killer Cells in Gastric Cancer.

Authors:  Yu Du; Yongchang Wei
Journal:  Front Immunol       Date:  2019-01-21       Impact factor: 7.561

Review 6.  Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.

Authors:  Yuqing Cao; Xiaoyu Wang; Tianqiang Jin; Yu Tian; Chaoliu Dai; Crystal Widarma; Rui Song; Feng Xu
Journal:  Signal Transduct Target Ther       Date:  2020-10-29

7.  CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.

Authors:  Takayuki Morimoto; Tsutomu Nakazawa; Ryosuke Matsuda; Fumihiko Nishimura; Mitsutoshi Nakamura; Shuichi Yamada; Ichiro Nakagawa; Young-Soo Park; Takahiro Tsujimura; Hiroyuki Nakase
Journal:  Int J Mol Sci       Date:  2021-03-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.